FDA Approves ‘First-in-Class’ NDSRI for ADHD in Adults and Children

SIMTRIYO is a newly approved central nervous system medication to help treat ADHD in children and adults. Tom Werner/DigitalVision/Getty Images Federal regulators have approved a new medication to help manage attention deficit hyperactivity disorder (ADHD). SIMTRIYO is a daily tablet authorized for adults and children 6 years and older who weigh at least 44 pounds. Experts say the new medication could be an important additional asset in the treatment and management of ADHD. A new medication to help treat attention deficit hyperactivity disorder (ADHD) will be available later this year. Otsuka Pharmaceutical has received approval from the Food and Drug Administration (FDA) for SIMTRIYO, a daily extended-relief tablet that contains the active ingredient centanafadine. The new medication is approved for use in adults and children 6 years and older who weigh at least 44 pounds. Otsuka officials say their drug is the first norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) to treat ADHD. SIMTRIYO “introduces a new treatment approach for patients and healthcare professionals managing this complex and highly individualized condition.” “The approval of SIMTRIYO …